Featured Research

from universities, journals, and other organizations

ADAM-12 gene could hold key to cancer, arthritis and cardiac treatments

Date:
March 9, 2011
Source:
University of Missouri-Columbia
Summary:
ADAM-12 is not only the name of a 1970s television police drama -- it's also the gene that researchers believe could be an important element in the fight against cancer, arthritis, and cardiac hypertrophy, or thickening of the heart's walls.

ADAM-12 is not only the name of a 1970's television police drama -- it's also the gene that University of Missouri researchers believe could be an important element in the fight against cancer, arthritis, and cardiac hypertrophy, or thickening of the heart's walls.

Alpana Ray, research associate professor in the MU College of Veterinary Medicine, and a team of researchers including Bimal Ray, professor of Veterinary Pathobiology, have been studying the ADAM family of genes for several years. Alpana Ray's latest publication in the Proceedings of the National Academy of Sciences (PNAS) discusses one pathway by which the ADAM-12 gene could be regulated, a process that could eventually be used as part of a treatment plan.

Scientists know that ADAM-12 is normally found in very low levels in adults, but during cancer, arthritis and cardiac hypertrophy, ADAM-12 level goes up. The only time it is normal to find a high level of the gene is during pregnancy, when ADAM-12 can be found in the placenta.

At the molecular level, Ray's team found a Z-DNA-binding silencer element that keeps the level of ADAM-12 low in normal conditions. They believe that if they could alter Z-DNA-binding silencer, new therapies could be right around the corner.

"We are finding that in the placenta, where ADAM-12 is highly expressed, the repressor protein (Z-DNA-binding protein) is inactive. In other tissues, where ADAM-12 expression is low, the repressor is active," Alpana Ray said. "What we don't know is how it actually works. We know co-factors are at work here. If we can identify the class of proteins that interact with Z-DNA repressor, it could lead to many therapeutic applications."

Because ADAM-12 is a versatile gene, it may play a role in metastasis during which cancer cells travel throughout the body and spread to other organs.

"We know that ADAM-12 causes cells to anchor to one another, and we know that ADAM-12 allows cancer cells to proliferate," said Alpana Ray.

Bimal Ray notes that the next phase of the work would be to determine how the Z-DNA-binding protein works.

"Most of the success in cancer therapy lies in a combination of approaches and chemotherapies, and this could become another piece of the puzzle that leads to the cure," Bimal Ray said.


Story Source:

The above story is based on materials provided by University of Missouri-Columbia. Note: Materials may be edited for content and length.


Journal Reference:

  1. B. K. Ray, S. Dhar, A. Shakya, A. Ray. Z-DNA-forming silencer in the first exon regulates human ADAM-12 gene expression. Proceedings of the National Academy of Sciences, 2010; 108 (1): 103 DOI: 10.1073/pnas.1008831108

Cite This Page:

University of Missouri-Columbia. "ADAM-12 gene could hold key to cancer, arthritis and cardiac treatments." ScienceDaily. ScienceDaily, 9 March 2011. <www.sciencedaily.com/releases/2011/03/110308173422.htm>.
University of Missouri-Columbia. (2011, March 9). ADAM-12 gene could hold key to cancer, arthritis and cardiac treatments. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/03/110308173422.htm
University of Missouri-Columbia. "ADAM-12 gene could hold key to cancer, arthritis and cardiac treatments." ScienceDaily. www.sciencedaily.com/releases/2011/03/110308173422.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins